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Abstract
Background: Multiple sclerosis (MS) is a leading cause of disability in young adults. Susceptibility to MS is determined by
environmental exposure on the background of genetic risk factors. A previous meta-analysis suggested that smoking was
an important risk factor for MS but many other studies have been published since then.
Methods/Principal Findings: We performed a Medline search to identify articles published that investigated MS risk
following cigarette smoking. A total of 14 articles were included in this study. This represented data on 3,052 cases and
457,619 controls. We analysed these studies in both a conservative (limiting our analysis to only those where smoking
behaviour was described prior to disease onset) and non-conservative manner. Our results show that smoking is associated
with MS susceptibility (conservative: risk ratio (RR) 1.48, 95% confidence interval (CI) 1.35–1.63, p,10215; non-conservative:
RR 1.52, 95% CI 1.39–1.66, p,10219). We also analysed 4 studies reporting risk of secondary progression in MS and found
that this fell just short of statistical significance with considerable heterogeneity (RR 1.88, 95% CI 0.98–3.61, p = 0.06).
Discussion: Our results demonstrate that cigarette smoking is important in determining MS susceptibility but the effect on
the progression of disease is less certain. Further work is needed to understand the mechanism behind this association and
how smoking integrates with other established risk factors.
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Introduction
Multiple sclerosis (MS) is a complex neurological condition
characterised by demyelination and axonal loss.[1] The nature versus
nurture argument has largely settled into a model in which many
genetic and environmental factors interact at different times prior to
and following the clinical onset of MS to determine susceptibility
and the clinical phenotype expressed.[2] These factors are currently
thought to include the Human Leukocyte Antigen (HLA) region,
smoking, Epstein-Barr virus (EBV) and vitamin D.[3,4,5]
Early case-control studies suggested that a history of smoking
could play a role in MS susceptibility, but either fell slightly short
of formal significance or analysed a large number of possible
variables simultaneously.[6,7] Since then a number of case-control
and population cohort studies have been performed with near
universal agreement that smoking cigarettes increases susceptibility
to MS.[4,8,9,10,11,12,13,14,15,16,17,18] Evidence from New
Zealand suggests that smoking behaviour may contribute to the
latitudinal distribution of MS risk there.[19,20]
A previous meta-analysis of six studies published in 2007
demonstrated an overall risk ratio (RR) of 1.24 (95% confidence
interval (CI) 1.04–1.48) with a p-value of 0.01 in the most
conservative model used.[21] Since this was published other
much larger studies have been directed towards understanding
the association between smoking cigarettes and MS susceptibility.
There is also evidence from analysing several case-control cohorts
in parallel that smoking behaviour does not change significantly
following diagnosis, suggesting that studies examining current
smoking behaviour may also be informative.[4] Risk prediction in
MS is a nascent field but accurate estimates of disease
susceptibility in relation to environmental factors are clearly
important for the success of any such predictions.[22] The
relationship between smoking and secondary progression is
currently highly controversial, with some studies suggesting an
increased risk of progression and others showing no ef-
fect.[12,23,24,25,26]
In this study we aimed to broaden the previous meta-
analysis to include all subsequently published and informative
studies of smoking behaviour and MS risk. Secondarily we
aimed to establish any correlation between both smoking and
latitude and between smoking and the risk of secondary progression
in MS.
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Methods
Search Strategy
We searched OLDMEDLINE and MEDLINE from 1960 to
May 2010 with the phrase: ‘‘(smok* OR cigarett*) AND (multiple
sclerosis OR ms)’’. We hand-searched abstracts generated from
this search term for cohort or case-control studies and examined
references of these articles for potential additional studies. We
included studies if they reported smoking behaviour, were either
case-control or cohort studies, and had a dedicated control group.
Studies were excluded if they gave insufficient data to calculate
95% CIs for RRs or smoking behaviour varied throughout the
reported study period. Experts in the field were unaware of any
ongoing unpublished studies for inclusion.
Statistical analysis
We used the generic inverse variance with random effects model
in Reference Manager 5.0 to calculate the overall RR, 95% CI and
test statistic for the interaction and heterogeneity of studies. Using
the rare disease assumption, we combined estimates of odds ratio
(OR) and RR [27]. For papers not reporting RR and 95% CIs but
with sufficient information to calculate these, we used the methods
described in [28]. We performed meta-analysis separately using a
conservative (including only studies where smoking behaviour was
described prior to disease onset) and non-conservative (all studies
regardless of whether smoking behaviour was prior to onset or
current) models. RRs were subsequently calculated for subgroups of
studies and compared between case-control and cohort studies. We
extracted latitude from papers based on either the latitude of the
study centre if performed in a distinct region or the geographical
midpoint of the country if a national study. We tested for an
interaction between latitude and sex-ratio by both a comparison of
RRs based on the median value for each factor and also performed
linear weighted fit on the natural log of RRs in MATLAB.
Results
Included studies in smoking and MS susceptibility
Our search criteria produced 1,490 studies. We identified 14
studies for inclusion in the MS susceptibility arm of the meta-
analysis.[4,6,7,8,9,10,11,12,13,14,15,16,17,18] The details of the
studies included are shown in supplementary table S1. These
studies represent data from 3,052 cases and 457,619 controls. We
excluded one study reporting smoking throughout pregnancy as
the frequency of smoking changed throughout the study
period.[29] We excluded two studies because insufficient data
Figure 1. Forest plot of smoking and multiple sclerosis risk (conservative model).
doi:10.1371/journal.pone.0016149.g001
Figure 2. Forest plot of smoking and multiple sclerosis risk (non-conservative model).
doi:10.1371/journal.pone.0016149.g002
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was described to calculate 95% CI for RR and the authors could
not be contacted.[30,31] Two additional studies were excluded
because they did not include a control group.[32,33] A number of
studies were not included as they contained duplicate smoking
data on a cohort already included in the meta-analy-
sis.[34,35,36,37] We also excluded the duplicate data published
in the paper by Simon et al.[4]
Smoking and MS susceptibility
10 studies were suitable for inclusion in the conservative model
of smoking and MS risk. This showed a highly significant
increased risk of MS associated with smoking with no significant
statistical heterogeneity (RR 1.48, 95% CI 1.35–1.63, p,10215,
heterogeneity: x2 = 7.38, p = 0.60; figure 1). Including all 14
studies in the non-conservative model yielded very similar results
(RR 1.52, 95% CI 1.39–1.66, p,10219, heterogeneity: x2 = 12.99,
p = 0.45; figure 2). There were no significant differences detected
when comparing subgroups of studies based on design or
diagnostic criteria, or when dichotomised based on median
latitude or sex-ratio (excluding studies looking exclusively at either
males or females) (table 1). Effect sizes of individual studies
appeared to be uniformly distributed around the meta-analysis
effect size, suggesting no large degree of publication bias
(figure 3).
Interaction with latitude and sex-ratio
We tested both latitude and sex-ratio for correlation with the
natural log of RR for each study using linear weighted fit
(figure 4). No significant correlation was found for either
(latitude: r2,0.01, p= 0.99; sex-ratio: r2 = 0.09, p = 0.40).
Figure 3. Funnel plot of all 14 susceptibility studies. Overall (non-conservative) meta-analysis risk ratio is shown as a dotted line.
doi:10.1371/journal.pone.0016149.g003
Table 1. Relative risk and 95% confidence intervals for different subgroups of studies.
Subgroup of studies Relative risk Lower 95% CI Upper 95% CI
number of
studies
p-value for
comparison
Case-control 1.49 1.35 1.66 11 0.65
Cohort 1.58 1.25 2.00 3
Interview/medical records smoking data 1.48 1.24 1.76 6 0.71
Questionnaire/unclear smoking data 1.54 1.38 1.72 8
Diagnostic criteria 1.50 1.31 1.70 8 0.66
Physician/self-reported/methods not reported 1.57 1.34 1.84 6
Latitude ,46 1.61 1.37 1.88 7 0.41
Latitude $46 1.48 1.30 1.67 7
Sex-ratio ,2.13 1.46 1.14 1.87 5 0.89
Sex-ratio $2.13 1.49 1.32 1.69 5
P-values for comparison between subgroups are also shown.
doi:10.1371/journal.pone.0016149.t001
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Smoking and secondary progression in MS
We located 5 studies reporting data on secondary progression in
MS and smoking behaviour.[12,23,24,25,26] Pittas and colleagues
gave RR per pack-year rather than for smokers versus non-smokers
and so this could not be included in the final analysis.[26] Our
meta-analysis of the remaining 4 studies (supplementary table
S1) showed a smoking RR for progression from relapsing-
remitting MS to secondary progressive MS that fell just short of
significance as well as highly significant statistical heterogeneity
(RR 1.88, 95% CI 0.98–3.61, p = 0.06, heterogeneity: x2 = 13.76,
p = 0.003; figure 5).
Discussion
Our meta-analysis includes data on a large number of MS cases
and controls. It is firmly established that smoking cigarettes is
associated with MS susceptibility but evidence suggests that this
environmental factor alone is unlikely to account for either the
global variation in prevalence.
The quality of studies varies widely as detailed in table S1. Our
sensitivity analysis suggests that the specific diagnostic criteria or
type of smoking data used make little difference to the strength of
the relationship between MS susceptibility and smoking (table 1).
Although most studies controlled for many confounding variables
such as age, sex and latitude, it must be acknowledged that other,
unknown confounders could be responsible for the effect observed.
We find no effect of latitude on risk of MS with smoking; however
differing degrees of migration in individual study populations may
mean that we have missed a latitudinal effect.
A key aspect in establishing causation of any environmental
factor is an interaction between susceptibility and dose [38]. Many
of the studies detailed in this meta-analysis did demonstrate
increasing MS susceptibility with increasing numbers of cigarettes
smoked [6,9,10,11,16] but this was not a universal finding [7,13].
Figure 4. Plots of relative risk against latitude and sex-ratio. Error bars show 95% confidence intervals of relative risk estimates.
doi:10.1371/journal.pone.0016149.g004
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The significant association between the degree of susceptibility to
MS and pack-years smoked suggests that smoking may have more
of an effect on susceptibility earlier in life, although without the
exact numbers of cigarettes per day available, this is difficult to
assess [11]. Unfortunately heterogeneity in how this data was
recorded (pack-years, cigarettes per day etc.) renders meta-analysis
of these aspects of studies problematic.
Our results are suggestive of an association between smoking
and risk of secondary progressive MS, but the high level of
heterogeneity between studies, both in design and statistical
outcomes, limits the ability to draw firm conclusions. However, the
demonstration of a dose-response effect on disease progression and
disease severity is suggestive of a causal link [25,26]. Several
studies demonstrate that smoking at an early age increases the
probability of progressive and severe MS [25,26].
The mechanism by which smoking affects the susceptibility to
and progression of MS is unclear. From population-based studies
of tobacco snuff use, which does not appear to increase the risk of
MS, it does not appear to be mediated solely by nicotine.[8,10] It
seems more likely that the mechanism involves components of
cigarette smoke, a hypothesis supported by a study showing that
the risk of MS may be increased with biochemical evidence of
passive smoke exposure.[39] One highly attractive molecular
candidate is nitric oxide, which has putative roles in demyelination
and axonal loss.[40,41] Cigarette smoke has a well-established role
in susceptibility to autoimmune diseases, making a biological effect
on the immune system highly probable.[42] Animal models have
suggested that smoke exposure affects several compartments of the
immune system, including innate immunity, B- and T-lympho-
cytes, and natural killer cells.[43,44,45] In rheumatoid arthritis, an
autoimmune disease in which smoking is important in determining
susceptibility, an interaction was identified between HLA alleles,
cigarette smoking and immunity to a-enolase.[46] It is possible
that the mechanism linking smoking and MS susceptibility may
involve similar autoimmunity against proteins with post-transla-
tional modifications. Another possibility is that smoking could
increase the risk of upper respiratory tract infections, an
established risk factor for MS [47,48].
As well as elucidating the mechanism(s) through which smoking
affects MS susceptibility and, potentially, progression, future
studies should investigate how environmental factors interact to
determine MS risk. Simon and colleagues have already shown that
high titres of antibodies against EBV antigens interact in a
multiplicative manner with smoking on MS susceptibility,
although the mechanism by which this occurs remains unprov-
en.[4] Although Simon et al. did not find an interaction between
HLA alleles and smoking, evidence exists in other autoimmune
diseases that this may occur.[46,49,50] Also of interest would be
the any alteration in sex specific aspects of MS risk following
smoking and whether this risk has changed over time. Given the
increasing sex-ratio observed in MS, it is possible that altered
smoking behaviour may explain at least part of this trend [51,52].
It is only by combining risk factors that patient-centred prediction
of MS susceptibility will become a possibility.
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